Venlafaxin Actavis Hart forðahylki 75 mg Islandija - islandščina - LYFJASTOFNUN (Icelandic Medicines Agency)

venlafaxin actavis hart forðahylki 75 mg

actavis group ptc ehf. - venlafaxinum hýdróklóríð - hart forðahylki - 75 mg

Venlafaxin Medical Valley Forðatafla 225 mg Islandija - islandščina - LYFJASTOFNUN (Icelandic Medicines Agency)

venlafaxin medical valley forðatafla 225 mg

medical valley invest ab - venlafaxinum hýdróklóríð - forðatafla - 225 mg

Cerdelga Evropska unija - islandščina - EMA (European Medicines Agency)

cerdelga

sanofi b.v. - eliglustat - gauchersjúkdómur - Önnur meltingarvegi og efnaskipti vörur, - cerdelga er ætlað til lengri tíma meðferð fullorðinn sjúklinga með eins sjúkdómur tegund 1 (gd1), sem eru cyp2d6 léleg metabolisers (fyrirtíðaspennu), millistig metabolisers (skilaboð) eða mikla metabolisers (sjúkrabíl).

Orladeyo Evropska unija - islandščina - EMA (European Medicines Agency)

orladeyo

biocryst ireland limited - berotralstat dihydrochloride - ofsabjúgur, arfgengur - other hematological agents - orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in adult and adolescent patients aged 12 years and older.

Inrebic Evropska unija - islandščina - EMA (European Medicines Agency)

inrebic

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - Æxlishemjandi lyf - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Livtencity Evropska unija - islandščina - EMA (European Medicines Agency)

livtencity

takeda pharmaceuticals international ag ireland branch - maribavir - cytomegalovirus sýkingar - veirueyðandi lyf til almennrar notkunar - livtencity is indicated for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (hsct) or solid organ transplant (sot). Íhuga ætti að opinbera leiðsögn á réttri notkun af veirum.